Sugata, Kenji
Matsunaga, Yukiko
Yamashita, Yuki
Nakatsugawa, Munehide
Guo, Tingxi
Halabelian, Levon http://orcid.org/0000-0003-4361-3619
Ohashi, Yota
Saso, Kayoko
Rahman, Muhammed A.
Anczurowski, Mark
Wang, Chung-Hsi
Murata, Kenji
Saijo, Hiroshi
Kagoya, Yuki
Ly, Dalam http://orcid.org/0000-0002-1177-0225
Burt, Brian D.
Butler, Marcus O. http://orcid.org/0000-0002-9840-7057
Mak, Tak W.
Hirano, Naoto http://orcid.org/0000-0001-9070-4754
Funding for this research was provided by:
Uehara Memorial Foundation
Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada
Province of Ontario
Frederick Banting and Charles Best Canada
Mitacs Internship
MEXT | Japan Society for the Promotion of Science
Guglietti fellowship
Princess Margaret Cancer Foundation
Ontario Institute for Cancer Research (IA-039)
Princess Margaret Cancer Centre Innovation Accelerator Fund Ira Schneider Memorial Cancer Research Foundation
Article History
Received: 30 July 2019
Accepted: 15 January 2021
First Online: 1 March 2021
Competing interests
: M.O.B. has served on advisory boards for Merck, BMS, Novartis, GSK, Immunocore, Immunovaccine, Sanofi and EMD Serono and received research funding for investigator-initiated clinical trials from Merck and Takara Bio. N.H. has received research funding from Takara Bio and served as a consultant for Takara Bio. The University Health Network has filed a patent application related to this study on which N.H., K. Sugata, Y.Y., M.N., K. Saso, M.A.R. and T.G. are named as inventors. T.W.M. and N.H. are cofounders and have equity in TCRyption to which the technologies used in this study have been licensed.